<qa>  What is the maximum dose of MT supplement?Following the last single dose assessment and an ensuing 7-day minimum wash-out period, subjects will initiate treatment of a 28-day treatment exposure to the MT supplement 175 mg 140 mg SM at the generally recommended and clinically studied dosage of one capsule thrice daily NLM, 2000. A 28-day course is selected to assure steady-state is reached and to surpass the duration of any other published pharmacokinetic studies of SM in human subjects which have generally been of brief duration. In addition, this extended dosing assessment will allow for the gathering of pilot data on the antioxidant potential of SM via measurements of urinary isoprostanes. Finally, an assessment of treatment-emergent adverse effects and tolerability will be made. Subjects will report to the outpatient GCRC on 4 separate occasions to pick up a 7-day supply of SM at which time a TESS will be administered. At the initial visit to the GCRC to obtain the first weeks supply of MT, subjects will provide a urine sample for baseline measurement of urinary isoprostanes and creatinine. After 28 days of treatment subjects will report to the GCRC for the determination of steady-state concentrations of SMs in plasma and urine. A blood draw will be performed immediately prior to dosing with the MT Ctrough and 0.5, 1.0, 2.0, 3.0 and 4.0 and 8.0 following MT dosing. Based upon available published data, these timepoints should be sufficient to capture the Cmax for all flavonoids of interest despite interindividual variability. Additionally, subjects will provide a morning urine sample for analysis of urinary isoprostane and creatinine. 